NCT05661110 is a clinical trial of Observational in Gastric Cancer, sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University.

Who is sponsoring NCT05661110?

NCT05661110 is sponsored by Affiliated Cancer Hospital & Institute of Guangzhou Medical University.

What drugs are being tested in NCT05661110?

Interventions in NCT05661110: Observational.

What condition does NCT05661110 study?

NCT05661110 studies Gastric Cancer.

Is NCT05661110 still recruiting?

NCT05661110 is currently not yet recruiting. Last updated 22 December 2022.

Last reviewed 2022-12-22 · How we verify

NCT05661110

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Biomarker Analysis of HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis

Not yet recruiting Last updated 22 December 2022

What this trial tests

trial testing Observational in Gastric Cancer in 46 participants. Not yet recruiting.

Timeline

1 January 2023

Primary endpoint
31 March 2025

31 December 2027

Quick facts

Lead sponsor	Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Status	Not yet recruiting
Study type	OBSERVATIONAL
Enrollment	46
Start date	1 January 2023
Primary completion	31 March 2025
Estimated completion	31 December 2027

Drugs / interventions tested

Observational — full drug profile →

Conditions studied

Gastric Cancer — all drugs for Gastric Cancer →

Sponsor

Affiliated Cancer Hospital & Institute of Guangzhou Medical University

Who can join

Adults 18 to 75, any sex, with Gastric Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A single-center, observational study, integrated biomarker analysis of HIPEC combined Programmed cell death 1 /Programmed cell death 1 ligand 1(PD1/PDL1)inhibitor in previously treated patients of advanced gastric cancer with peritoneal metastasis. Tests will be performed on tumor tissue and blood samples, and imaging assessments will be reviewed in order to monitor how well each patient responds to treatment. This is an observational study, so participants will not receive cancer treatment, other than the treatment received as standard of care.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Clinical applications and perspectives of circulating tumor DNA in gastric cancer.
Li JH, Zhang DY, Zhu JM, Dong L. · · 2024 · cited 14× · PMID 38184573 · DOI 10.1186/s12935-024-03209-4
Blood-Based Surveillance Biomarkers for Gastroesophageal Cancers.
Dadgar N, Anees M, Sherry C, Park HY, et al · · 2025 · cited 2× · PMID 41228346 · DOI 10.3390/cancers17213552

Verify or expand the search:

Other trials of Observational

Trials testing the same drug.

NCT07356700 — Deciphering the Factors of Longevity Through a Multi-Omics Study in Long-Lived Individuals in Hong Kong · not yet recruiting
NCT07381751 — Artificial Intelligence-assisted MDS-UPDRS Assessment for Parkinson's Disease · not yet recruiting
NCT07347574 — NeuroCare Community Project: A Community Based Prospective Observational Study for Early Alzheimer's Detection in HK · not yet recruiting
NCT07338968 — A Long-Term Follow-Up Study of Subjects Completing the AU-011-301(CoMpass) for Early Choroidal Melanoma · not yet recruiting
NCT06792994 — A Prospective Observational Trial to Assess Treatment Sequences and Factors That Impact Overall Sur-vival in Patients Wi · not yet recruiting

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

NCT07525765 — AI-assisted Decision-making of Reoperation for Postoperative Bleeding of Gastric Cancer · recruiting
NCT07464470 — Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Gastroesophageal Cancers · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07431281 — Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta · Phase 3 · recruiting
NCT07448493 — Local Treatment Strategies for Brain Metastases of Gastric and Esophageal Cancer · active not recruiting

Other Affiliated Cancer Hospital & Institute of Guangzhou Medical University trials

Trials by the same sponsor.

NCT07286240 — QL1706 Combined With Chemotherapy and Anlotinib for the Treatment of Recurrent Ovarian Cancer · Phase 2 · recruiting
NCT07286253 — QL1706 Plus Chemotherapy as Neoadjuvant Therapy for Locally Advanced Cervical Cancer: A Phase II Trial · Phase 2 · recruiting
NCT06594172 — Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy · Phase 2 · not yet recruiting
NCT06570538 — Analgesic Efficacy of an Opioid-free Postoperative Pain Management Strategy Versus a Conventional Opioid-based Strategy · EARLY_PHASE1 · not yet recruiting
NCT06327932 — HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer · Phase 3 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05661110 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Last refreshed: 22 December 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05661110.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing